Details of the Drug

General Information of Drug (ID: DM3ADGP)

Drug Name
Rhucin
Synonyms
sildenafil; 139755-83-2; VIAGRA; Sildenafil [INN:BAN]; UK-92480; UNII-3M7OB98Y7H; UK-92,480-10; C22H30N6O4S; HSDB 7305; CHEMBL192; UK 92480-10; CHEBI:9139; 3M7OB98Y7H; 1-((3-(4,7-Dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo(4,3-d)pyrimidin-5-yl)-4-ethoxyphenyl)sulfonyl)-4-methylpiperazine; BNRNXUUZRGQAQC-UHFFFAOYSA-N; 5-(2-Ethoxy-5-((4-methylpiperazin-1-yl)sulfonyl)phenyl)-1-methyl-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-7(6H)-one; Sildenafil
Indication
Disease Entry ICD 11 Status REF
Erectile dysfunction HA01.1 Approved [1], [2]
Hereditary angioedema 4A00.14 Approved [3], [4]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 474.6
Topological Polar Surface Area (xlogp) 1.5
Rotatable Bond Count (rotbonds) 7
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 8
Chemical Identifiers
Formula
C22H30N6O4S
IUPAC Name
5-[2-ethoxy-5-(4-methylpiperazin-1-yl)sulfonylphenyl]-1-methyl-3-propyl-6H-pyrazolo[4,3-d]pyrimidin-7-one
Canonical SMILES
CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C
InChI
InChI=1S/C22H30N6O4S/c1-5-7-17-19-20(27(4)25-17)22(29)24-21(23-19)16-14-15(8-9-18(16)32-6-2)33(30,31)28-12-10-26(3)11-13-28/h8-9,14H,5-7,10-13H2,1-4H3,(H,23,24,29)
InChIKey
BNRNXUUZRGQAQC-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
135398744
ChEBI ID
CHEBI:9139
CAS Number
139755-83-2
TTD ID
D0Z7ZM
VARIDT ID
DR00565
ACDINA ID
D00622

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
C1 esterase inhibitor (SERPING1) TTVQ6R9 IC1_HUMAN Modulator [3], [4]
Phosphodiesterase 5A (PDE5A) TTJ0IQB PDE5A_HUMAN Inhibitor [5], [6], [7], [8]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Erectile dysfunction
ICD Disease Classification HA01.1
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Phosphodiesterase 5A (PDE5A) DTT PDE5A 1.60E-01 -0.25 -0.99
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Rhucin
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Berotralstat DMWA2DZ Moderate Decreased metabolism of Rhucin caused by Berotralstat mediated inhibition of CYP450 enzyme. Innate/adaptive immunodeficiency [4A00] [20]
Coadministration of a Drug Treating the Disease Different from Rhucin (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Ivosidenib DM8S6T7 Moderate Increased metabolism of Rhucin caused by Ivosidenib mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [20]
Arn-509 DMT81LZ Moderate Increased metabolism of Rhucin caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [20]
Mitotane DMU1GX0 Moderate Increased metabolism of Rhucin caused by Mitotane mediated induction of CYP450 enzyme. Adrenal cancer [2D11] [20]
Ranolazine DM0C9IL Moderate Decreased metabolism of Rhucin caused by Ranolazine mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [20]
Dronedarone DMA8FS5 Moderate Decreased metabolism of Rhucin caused by Dronedarone mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [20]
Butalbital DM9J04X Moderate Increased metabolism of Rhucin caused by Butalbital mediated induction of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [20]
Methylphenobarbital DMDSWAG Moderate Increased metabolism of Rhucin caused by Methylphenobarbital mediated induction of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [20]
Voriconazole DMAOL2S Major Decreased metabolism of Rhucin caused by Voriconazole mediated inhibition of CYP450 enzyme. Aspergillosis [1F20] [21]
Zafirlukast DMHNQOG Moderate Decreased metabolism of Rhucin caused by Zafirlukast mediated inhibition of CYP450 enzyme. Asthma [CA23] [20]
Ciprofloxacin XR DM2NLS9 Moderate Decreased metabolism of Rhucin caused by Ciprofloxacin XR mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [20]
Dalfopristin DM4LTKV Moderate Decreased metabolism of Rhucin caused by Dalfopristin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [22]
Clarithromycin DM4M1SG Major Decreased metabolism of Rhucin caused by Clarithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [21]
Chloramphenicol DMFXEWT Moderate Decreased metabolism of Rhucin caused by Chloramphenicol mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [20]
Linezolid DMGFPU2 Moderate Additive hypotensive effects by the combination of Rhucin and Linezolid. Bacterial infection [1A00-1C4Z] [23]
Troleandomycin DMUZNIG Major Decreased metabolism of Rhucin caused by Troleandomycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [21]
Telithromycin DMZ4P3A Major Decreased metabolism of Rhucin caused by Telithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [21]
Erdafitinib DMI782S Moderate Increased metabolism of Rhucin caused by Erdafitinib mediated induction of CYP450 enzyme. Bladder cancer [2C94] [24]
Pexidartinib DMS2J0Z Moderate Increased metabolism of Rhucin caused by Pexidartinib mediated induction of CYP450 enzyme. Bone/articular cartilage neoplasm [2F7B] [20]
Lapatinib DM3BH1Y Moderate Decreased metabolism of Rhucin caused by Lapatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [20]
Tucatinib DMBESUA Major Decreased metabolism of Rhucin caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [21]
Palbociclib DMD7L94 Moderate Decreased metabolism of Rhucin caused by Palbociclib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [20]
Alpelisib DMEXMYK Moderate Increased metabolism of Rhucin caused by Alpelisib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [25]
Grepafloxacin DMGLX0T Moderate Decreased metabolism of Rhucin caused by Grepafloxacin mediated inhibition of CYP450 enzyme. Bronchitis [CA20] [20]
Secobarbital DM14RF5 Moderate Increased metabolism of Rhucin caused by Secobarbital mediated induction of CYP450 enzyme. Chronic insomnia [7A00] [20]
Phenylbutazone DMAYL0T Moderate Increased metabolism of Rhucin caused by Phenylbutazone mediated induction of CYP450 enzyme. Chronic pain [MG30] [20]
Anisindione DM2C48U Moderate Increased risk of bleeding by the combination of Rhucin and Anisindione. Coagulation defect [3B10] [26]
Mifepristone DMGZQEF Moderate Decreased metabolism of Rhucin caused by Mifepristone mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [21]
Aminoglutethimide DMWFHMZ Moderate Increased metabolism of Rhucin caused by Aminoglutethimide mediated induction of CYP450 enzyme. Cushing syndrome [5A70] [20]
Ivacaftor DMZC1HS Moderate Decreased metabolism of Rhucin caused by Ivacaftor mediated inhibition of CYP450 enzyme. Cystic fibrosis [CA25] [20]
Ethanol DMDRQZU Moderate Additive hypotensive effects by the combination of Rhucin and Ethanol. Cystitis [GC00] [26]
Aprepitant DM053KT Moderate Decreased metabolism of Rhucin caused by Aprepitant mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [20]
Nefazodone DM4ZS8M Major Decreased metabolism of Rhucin caused by Nefazodone mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [21]
Selegiline DM6034S Moderate Additive hypotensive effects by the combination of Rhucin and Selegiline. Depression [6A70-6A7Z] [23]
Isocarboxazid DMAF1NB Moderate Additive hypotensive effects by the combination of Rhucin and Isocarboxazid. Depression [6A70-6A7Z] [23]
Tranylcypromine DMGB5RE Moderate Additive hypotensive effects by the combination of Rhucin and Tranylcypromine. Depression [6A70-6A7Z] [23]
Phenelzine DMHIDUE Moderate Additive hypotensive effects by the combination of Rhucin and Phenelzine. Depression [6A70-6A7Z] [23]
Griseofulvin DMK54YG Moderate Increased metabolism of Rhucin caused by Griseofulvin mediated induction of CYP450 enzyme. Dermatophytosis [1F28] [20]
Primidone DM0WX6I Moderate Increased metabolism of Rhucin caused by Primidone mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [20]
Felbamate DM1V5ZS Moderate Increased metabolism of Rhucin caused by Felbamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [20]
Oxcarbazepine DM5PU6O Moderate Increased metabolism of Rhucin caused by Oxcarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [20]
Cenobamate DMGOVHA Moderate Increased metabolism of Rhucin caused by Cenobamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [20]
Phenytoin DMNOKBV Moderate Increased metabolism of Rhucin caused by Phenytoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [20]
Fosphenytoin DMOX3LB Moderate Increased metabolism of Rhucin caused by Fosphenytoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [20]
Phenobarbital DMXZOCG Moderate Increased metabolism of Rhucin caused by Phenobarbital mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [20]
Carbamazepine DMZOLBI Moderate Increased metabolism of Rhucin caused by Carbamazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [20]
Tazemetostat DMWP1BH Moderate Increased metabolism of Rhucin caused by Tazemetostat mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [20]
Itraconazole DMCR1MV Major Decreased metabolism of Rhucin caused by Itraconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [21]
Clotrimazole DMMFCIH Moderate Decreased metabolism of Rhucin caused by Clotrimazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [20]
Miconazole DMPMYE8 Moderate Decreased metabolism of Rhucin caused by Miconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [27]
Ketoconazole DMPZI3Q Major Decreased metabolism of Rhucin caused by Ketoconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [21]
Cimetidine DMH61ZB Moderate Decreased metabolism of Rhucin caused by Cimetidine mediated inhibition of CYP450 enzyme. Gastro-oesophageal reflux disease [DA22] [20]
Sulfinpyrazone DMEV954 Moderate Increased metabolism of Rhucin caused by Sulfinpyrazone mediated induction of CYP450 enzyme. Gout [FA25] [20]
Boceprevir DMBSHMF Major Decreased metabolism of Rhucin caused by Boceprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [28]
Simeprevir DMLUA9D Moderate Decreased metabolism of Rhucin caused by Simeprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [29]
Telaprevir DMMRV29 Major Decreased metabolism of Rhucin caused by Telaprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [28]
Isoniazid DM5JVS3 Moderate Decreased metabolism of Rhucin caused by Isoniazid mediated inhibition of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [20]
Rifampin DMA8J1G Moderate Increased metabolism of Rhucin caused by Rifampin mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [20]
Rifapentine DMCHV4I Moderate Increased metabolism of Rhucin caused by Rifapentine mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [20]
Procarbazine DMIK367 Moderate Additive hypotensive effects by the combination of Rhucin and Procarbazine. Hodgkin lymphoma [2B30] [23]
Indinavir DM0T3YH Major Decreased metabolism of Rhucin caused by Indinavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [28]
Delavirdine DM3NF5G Major Decreased metabolism of Rhucin caused by Delavirdine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [21]
Fosamprenavir DM4W9B3 Major Decreased metabolism of Rhucin caused by Fosamprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [28]
Nevirapine DM6HX9B Moderate Increased metabolism of Rhucin caused by Nevirapine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [20]
Cobicistat DM6L4H2 Major Decreased metabolism of Rhucin caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [30]
Efavirenz DMC0GSJ Moderate Increased metabolism of Rhucin caused by Efavirenz mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [20]
Saquinavir DMG814N Major Decreased metabolism of Rhucin caused by Saquinavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [28]
Etravirine DMGV8QU Moderate Increased metabolism of Rhucin caused by Etravirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [31]
Amprenavir DMLMXE0 Major Decreased metabolism of Rhucin caused by Amprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [28]
Darunavir DMN3GCH Major Decreased metabolism of Rhucin caused by Darunavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [28]
Atazanavir DMSYRBX Major Decreased metabolism of Rhucin caused by Atazanavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [28]
Ritonavir DMU764S Major Decreased metabolism of Rhucin caused by Ritonavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [28]
BMS-201038 DMQTAGO Moderate Decreased metabolism of Rhucin caused by BMS-201038 mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [20]
Conivaptan DM1V329 Moderate Decreased metabolism of Rhucin caused by Conivaptan mediated inhibition of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [30]
Suvorexant DM0E6S3 Moderate Decreased metabolism of Rhucin caused by Suvorexant mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [20]
Amobarbital DM0GQ8N Moderate Increased metabolism of Rhucin caused by Amobarbital mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [20]
Butabarbital DMC5AST Moderate Increased metabolism of Rhucin caused by Butabarbital mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [20]
Pentobarbital DMFNH7L Moderate Increased metabolism of Rhucin caused by Pentobarbital mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [20]
Crizotinib DM4F29C Moderate Decreased metabolism of Rhucin caused by Crizotinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [20]
Brigatinib DM7W94S Moderate Increased metabolism of Rhucin caused by Brigatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [32]
Ceritinib DMB920Z Major Decreased metabolism of Rhucin caused by Ceritinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [21]
PF-06463922 DMKM7EW Moderate Increased metabolism of Rhucin caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [20]
Selpercatinib DMZR15V Moderate Decreased metabolism of Rhucin caused by Selpercatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [20]
Idelalisib DM602WT Major Decreased metabolism of Rhucin caused by Idelalisib mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [21]
IPI-145 DMWA24P Moderate Decreased metabolism of Rhucin caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [20]
Vemurafenib DM62UG5 Moderate Increased metabolism of Rhucin caused by Vemurafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [20]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Rhucin caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [20]
Danazol DML8KTN Moderate Decreased metabolism of Rhucin caused by Danazol mediated inhibition of CYP450 enzyme. Menstrual cycle bleeding disorder [GA20] [20]
Exjade DMHPRWG Moderate Decreased metabolism of Rhucin caused by Exjade mediated inhibition of CYP450 enzyme. Mineral absorption/transport disorder [5C64] [33]
Ozanimod DMT6AM2 Moderate Additive hypotensive effects by the combination of Rhucin and Ozanimod. Multiple sclerosis [8A40] [23]
Rifabutin DM1YBHK Moderate Increased metabolism of Rhucin caused by Rifabutin mediated induction of CYP450 enzyme. Mycobacterium infection [1B10-1B21] [20]
Bexarotene DMOBIKY Moderate Increased metabolism of Rhucin caused by Bexarotene mediated induction of CYP450 enzyme. Mycosis fungoides [2B01] [20]
Fedratinib DM4ZBK6 Moderate Decreased metabolism of Rhucin caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [20]
Nilotinib DM7HXWT Moderate Decreased metabolism of Rhucin caused by Nilotinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [20]
Imatinib DM7RJXL Moderate Decreased metabolism of Rhucin caused by Imatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [20]
Modafinil DMYILBE Minor Increased metabolism of Rhucin caused by Modafinil mediated induction of CYP450 enzyme. Narcolepsy [7A20] [34]
Netupitant DMEKAYI Moderate Decreased metabolism of Rhucin caused by Netupitant mediated inhibition of CYP450 enzyme. Nausea/vomiting [MD90] [22]
Entrectinib DMMPTLH Moderate Decreased metabolism of Rhucin caused by Entrectinib mediated inhibition of CYP450 enzyme. Non-small cell lung cancer [2C25] [20]
Rucaparib DM9PVX8 Moderate Decreased metabolism of Rhucin caused by Rucaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [20]
Safinamide DM0YWJC Moderate Additive hypotensive effects by the combination of Rhucin and Safinamide. Parkinsonism [8A00] [23]
Rasagiline DM3WKQ4 Moderate Additive hypotensive effects by the combination of Rhucin and Rasagiline. Parkinsonism [8A00] [23]
Abametapir DM2RX0I Moderate Decreased metabolism of Rhucin caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [35]
Lefamulin DME6G97 Moderate Decreased metabolism of Rhucin caused by Lefamulin mediated inhibition of CYP450 enzyme. Pneumonia [CA40] [36]
Lonafarnib DMGM2Z6 Major Decreased metabolism of Rhucin caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [21]
Enzalutamide DMGL19D Moderate Increased metabolism of Rhucin caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [20]
Bicalutamide DMZMSPF Moderate Decreased metabolism of Rhucin caused by Bicalutamide mediated inhibition of CYP450 enzyme. Prostate cancer [2C82] [20]
Bosentan DMIOGBU Moderate Decreased metabolism of Rhucin caused by Bosentan mediated inhibition of CYP450 enzyme. Pulmonary hypertension [BB01] [22]
Temsirolimus DMS104F Moderate Increased plasma concentrations of Rhucin and Temsirolimus due to competitive inhibition of the same metabolic pathway. Renal cell carcinoma [2C90] [37]
Dexamethasone DMMWZET Moderate Increased metabolism of Rhucin caused by Dexamethasone mediated induction of CYP450 enzyme. Rheumatoid arthritis [FA20] [20]
Nafcillin DMN9RPO Moderate Increased metabolism of Rhucin caused by Nafcillin mediated induction of CYP450 enzyme. Rheumatoid arthritis [FA20] [20]
Voxelotor DMCS6M5 Moderate Decreased metabolism of Rhucin caused by Voxelotor mediated inhibition of CYP450 enzyme. Sickle-cell disorder [3A51] [20]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Rhucin caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [26]
Larotrectinib DM26CQR Moderate Decreased metabolism of Rhucin caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [20]
Armodafinil DMGB035 Minor Increased metabolism of Rhucin caused by Armodafinil mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [34]
LEE011 DMMX75K Moderate Decreased metabolism of Rhucin caused by LEE011 mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [20]
Warfarin DMJYCVW Moderate Increased risk of bleeding by the combination of Rhucin and Warfarin. Supraventricular tachyarrhythmia [BC81] [26]
Fostamatinib DM6AUHV Moderate Decreased metabolism of Rhucin caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [38]
Brilinta DMBR01X Moderate Decreased metabolism of Rhucin caused by Brilinta mediated inhibition of CYP450 enzyme. Thrombosis [DB61-GB90] [20]
Dicumarol DMFQCB1 Moderate Increased risk of bleeding by the combination of Rhucin and Dicumarol. Thrombosis [DB61-GB90] [26]
Sirolimus DMGW1ID Moderate Increased plasma concentrations of Rhucin and Sirolimus due to competitive inhibition of the same metabolic pathway. Transplant rejection [NE84] [37]
Tacrolimus DMZ7XNQ Moderate Increased plasma concentrations of Rhucin and Tacrolimus due to competitive inhibition of the same metabolic pathway. Transplant rejection [NE84] [39]
Elagolix DMB2C0E Moderate Increased metabolism of Rhucin caused by Elagolix mediated induction of CYP450 enzyme. Uterine fibroid [2E86] [20]
Amiodarone DMUTEX3 Moderate Decreased metabolism of Rhucin caused by Amiodarone mediated inhibition of CYP450 enzyme. Ventricular tachyarrhythmia [BC71] [20]
⏷ Show the Full List of 122 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
FD&C blue no. 2 E00446 2723854 Colorant
Sodium stearyl fumarate E00545 23665634 lubricant
Sunset yellow FCF E00255 17730 Colorant
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Brushite E00392 104805 Diluent
Calcium hydrogenphosphate E00294 24441 Diluent
Carmellose sodium E00625 Not Available Disintegrant
Crospovidone E00626 Not Available Disintegrant
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Polyethylene glycol 3350 E00652 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 4000 E00654 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyvinyl alcohol E00666 Not Available Coating agent; Emulsion stabilizing agent; Film/Membrane-forming agent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Triacetin E00080 5541 Humectant; Plasticizing agent; Solvent
⏷ Show the Full List of 17 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Sildenafil 100 mg tablet 100 mg Oral Tablet Oral
Sildenafil 25 mg tablet 25 mg Oral Tablet Oral
Sildenafil 50 mg tablet 50 mg Oral Tablet Oral
Sildenafil 20 mg tablet 20 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4743).
2 Pharmacologic therapeutics for cardiac reperfusion injury. Expert Opin Emerg Drugs. 2007 Sep;12(3):367-88.
3 Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
4 Recombinant human c1 inhibitor (conestat alfa): in the treatment of angioedema attacks in hereditary angioedema. BioDrugs. 2012 Oct 1;26(5):315-23.
5 cGMP-hydrolytic activity and its inhibition by sildenafil in normal and failing human and mouse myocardium. J Pharmacol Exp Ther. 2009 Sep;330(3):884-91.
6 Efficacy and safety of sildenafil citrate (Viagra) in men with erectile dysfunction and spinal cord injury: a review. Urology. 2002 Sep;60(2 Suppl 2):49-57.
7 Knockouts model the 100 best-selling drugs--will they model the next 100 Nat Rev Drug Discov. 2003 Jan;2(1):38-51.
8 Phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction in patients with diabetes mellitus. Int J Impot Res. 2002 Dec;14(6):466-71.
9 Pulmonary arterial hypertension: the most devastating vascular complication of systemic sclerosis. Rheumatology (Oxford). 2009 Jun;48 Suppl 3:iii25-31.
10 Increased expression of the nitric oxide synthase gene and protein in corpus cavernosum by repeated dosing of udenafil in a rat model of chemical d... Asian J Androl. 2009 Jul;11(4):435-42.
11 The effect of vardenafil, a potent and highly selective phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction, on the cardiovascular response to exercise in patients with coronary artery disease. J Am Coll Cardiol. 2002 Dec 4;40(11):2006-12.
12 Anti-platelet therapy: phosphodiesterase inhibitors.Br J Clin Pharmacol.2011 Oct;72(4):634-46.
13 Effects of icariin on cGMP-specific PDE5 and cAMP-specific PDE4 activities. Asian J Androl. 2003 Mar;5(1):15-8.
14 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
15 Potent inhibition of human phosphodiesterase-5 by icariin derivatives. J Nat Prod. 2008 Sep;71(9):1513-7.
16 Exisulind induction of apoptosis involves guanosine 3',5'-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated beta-catenin. Cancer Res. 2000 Jul 1;60(13):3338-42.
17 Highlights of the society for medicinesresearch symposium held december 10th 2009 at the national heart and lung institute, London, UK. Drugs of the Future 2010, 35(4): 349-358.
18 Highly potent and selective chiral inhibitors of PDE5: an illustration of Pfeiffer's rule. Bioorg Med Chem Lett. 2008 Dec 1;18(23):6033-6.
19 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
20 Hyland R, Roe GH, Jones BC, Smith DA "Identification of the cytochrome P450 enzymes involved in the N-demethylation of sildenafil." Br J Clin Pharmaacol 51 (2001): 239-48. [PMID: 11298070]
21 Cerner Multum, Inc. "Australian Product Information.".
22 Product Information. Revatio (sildenafil). Pfizer U.S. Pharmaceuticals Group, New York, NY.
23 Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6. [PMID: 1116424]
24 Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
25 Product Information. Piqray (alpelisib). Novartis Pharmaceuticals, East Hanover, NJ.
26 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
27 Product Information. ORAVIG (miconazole). Strativa Pharmaceuticals, a Division of Par Pharmaceuticals, Inc., Woodcliff Lake, NJ.
28 Barry M, Mulcahy F, Merry C, Gibbons S, Back D "Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection." Clin Pharmacokinet 36 (1999): 289-304. [PMID: 10320951]
29 Product Information. Olysio (simeprevir). Janssen Pharmaceuticals, Titusville, NJ.
30 Hall MCS, Ahmad S "Interaction between sildenafil and HIV-1 combination therapy." Lancet 353 (1999): 2071-2. [PMID: 10376645]
31 Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
32 Product Information. Alunbrig (brigatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
33 Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
34 Doherty MM, Charman WN "The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?" Clin Pharmacokinet 41 (2002): 235-53. [PMID: 11978143]
35 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
36 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
37 Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
38 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
39 Christ B, Brockmeier D, Hauck EW, Friemann S "Interactions of sildenafil and tacrolimus in men with erectile dysfunction after kidney transplantation." Urology 58 (2001): 589-93. [PMID: 11597545]